Paper Details
- Home
- Paper Details
Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.
Author: GiesslerChristine, KangWonku, WeissMichael
Original Abstract of the Article :
It has been hypothesized that coronary vasoconstriction is involved in the cardiotoxic action of anthracyclines. The purpose of this study was to determine whether an increase in coronary resistance induced by idarubicin (IDA) or its primary circulating metabolite idarubicinol (IDOL) is correlated w...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1097/01.cad.0000185186.03099.31
データ提供：米国国立医学図書館（NLM）
Idarubicin and Idarubicinol: Navigating the Desert of Cardiotoxicity
Anthracyclines, a class of chemotherapy drugs used to treat various cancers, are like powerful desert warriors, capable of defeating cancer cells. However, like any powerful force, they can also have unintended consequences. This study, like a camel carefully navigating a desert landscape, investigates the potential cardiotoxicity of idarubicin (IDA) and its metabolite idarubicinol (IDOL). Researchers examine the effects of IDA and IDOL on coronary vascular resistance and vasoconstrictor responsiveness in rat hearts and isolated aorta and mesentery. The study found that both IDA and IDOL increased coronary vascular resistance and decreased vascular sensitivity to vasoconstrictor agonists.
Idarubicin and Idarubicinol: Understanding the Potential for Cardiotoxicity
This study sheds light on the potential cardiotoxicity of IDA and IDOL, highlighting the need for careful monitoring and management of cardiovascular function during treatment. The study’s findings underscore the importance of considering alternative treatment options when appropriate and balancing the benefits of chemotherapy with potential risks.
Navigating the Desert: Balancing the Benefits and Risks of Anthracycline Treatment
This research reminds us that the journey to conquering cancer is not without its challenges. Just as a camel navigates a desert landscape with vigilance, individuals undergoing anthracycline treatment should work closely with their healthcare providers to monitor their cardiovascular health and discuss potential treatment strategies.
Dr. Camel's Conclusion
This study provides valuable insights into the potential cardiotoxicity of idarubicin and idarubicinol, highlighting the need for careful monitoring and a balanced approach to managing cancer treatment. Like a wise camel traversing a desert, researchers continue to explore the complexities of cancer treatments, seeking to optimize outcomes while minimizing potential risks.
Date :
- Date Completed 2006-10-27
- Date Revised 2019-09-17
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.